Artivion Inc
NYSE:AORT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Artivion Inc
Cash from Operating Activities
Artivion Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Artivion Inc
NYSE:AORT
|
Cash from Operating Activities
$39.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Operating Activities
$4.5B
|
CAGR 3-Years
44%
|
CAGR 5-Years
25%
|
CAGR 10-Years
21%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash from Operating Activities
$1.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Operating Activities
$5B
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Operating Activities
$9.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Operating Activities
$3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
Artivion Inc
Glance View
In the heart of the biomedical landscape, Artivion Inc. emerges as a company fervently dedicated to extending and saving lives through advanced medical technologies. It is a principal innovator and supplier in cardiac and vascular surgery, carving its niche by providing unique products that serve critical therapeutic needs. Initially branded as CryoLife, the company redefined its mission and vision under the Artivion name post a strategic transformation, focusing on strategically enhancing its product portfolio. It crafts precision-engineered prosthetic heart valves, notably the On-X mechanical valve, which is renowned for its exceptional long-term durability and performance in reducing the need for anticoagulation therapy. Through its relentless innovation, Artivion ensures that its offerings are not only of high quality but also cost-effective, thereby widening the accessibility to life-saving technologies. This commitment to quality is underscored by their rigorous research and development efforts and regulatory compliance, ensuring every product meets global medical standards. Artivion's revenue engine is driven largely by its cardiovascular implantables and bioprosthetics used in vascular surgery, alongside tissue processing services that provide mitral, aortic, and pulmonary cardiac valves. By coupling advanced materials and sophisticated design, the organization enhances its presence in the global cardiovascular industry—serving hospitals, physicians, and patients alike. Its products are distributed through a combination of direct sales and distributor partnerships, broadening its geographical market presence from the United States to Europe, Asia, and beyond. Artivion stands not only as a supplier but as a strategic partner to clinicians, extending support and education to ensure optimal patient outcomes. Its strategic prowess in the competitive med-tech arena is an intricate mosaic of innovation, operational excellence, and a keen awareness of the pressing health challenges that afflict the global population. Through these concerted efforts, Artivion not only sustains its growth and shareholder value but continues its mission to improve life expectancy and quality around the world.
See Also
What is Artivion Inc's Cash from Operating Activities?
Cash from Operating Activities
39.9m
USD
Based on the financial report for Dec 31, 2025, Artivion Inc's Cash from Operating Activities amounts to 39.9m USD.
What is Artivion Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
26%
Over the last year, the Cash from Operating Activities growth was 79%.